Cocrystal of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid
(1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazole-2-ylcarbamoyl)cyclopentium was solved by forming co-crystals with gentilic acid, urea and nicotinamide. The problem of hygroscopicity and insufficient bioavailability of alkane carboxylic acids has achieved higher stability and bioavailability, and is suitable for drug development and treatment.
Patent Information
- Application Number
- CN202180021708.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-03-16
- Filing Date
- 2021-03-15
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2041-03-15
AI Technical Summary
The existing (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazole-2-ylcarbamoyl)cyclopentane carboxylic acids have hygroscopicity and bioavailability in drug development The problem of insufficient degree affects its pharmaceutical and therapeutic effects.
By forming eutectics with gentilic acid, urea and nicotinamide, the physicochemical and pharmacokinetic properties of the compounds are improved, including reducing hygroscopicity and improving melting point and bioavailability.
The formed eutectics significantly improve the stability and bioavailability of the compounds, allowing therapeutic effects at lower doses, and maintaining good solid state properties during storage and treatment.
Smart Images

Figure BDA0003848560800000011 
Figure BDA0003848560800000151 
Figure BDA0003848560800000152
Abstract
Description
Technical Field
[0001] The present invention relates to a novel co-crystal of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid which is an adenosine A1 adenosine receptor antagonist. The co-crystal can be used to treat or prevent diseases known to be improved by A1 adenosine receptor antagonism. Background Art
[0002] Adenosine A1 receptor antagonists can be used to treat or prevent various diseases, including hypertension, heart failure, ischemia, supraventricular arrhythmias, acute renal failure, myocardial reperfusion injury, asthma, allergic reactions including rhinitis and urticaria, scleroderma and autoimmune diseases such as multiple sclerosis. (Hocher, B, Adenosine A1 receptor antagonists in clinical research and development, Kidney International (2010) 78, 438–445; Haskó, G et al, Adenosine receptors: therapeutic aspects for inflammatory and immune diseases, Nature Reviews, volume 7, September 2008, 759).
[0003] Specifically, patent application WO2009 / 044250A1 discloses 5-cyano-1,3-thiazole derivatives, which are effective A1 adenosine receptor antagonists and can be used to treat the above diseases. In the patent application, 3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid, in particular the (1R,3S) stereoisomer is disclosed, and its structure is shown below:
[0004]
[0005] Co-crystals of 5-cyano-1,3-thiazole derivatives are not mentioned in the cited documents nor in other documents known to the applicant.
[0006] Although (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid has shown suitable pharmacological activity, there seems to be room for improvement in the physical and / or pharmacological properties of the compound, particularly its hygroscopicity and bioavailability. Improvements in the properties would facilitate further pharmaceutical development thereof into a drug.
[0007] Therefore, there is a need in the art to provide a method for improving the hygroscopicity and / or bioavailability of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid.
[0008] Therefore, it is highly desirable to develop a soluble and stable pharmaceutically acceptable form of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid with improved hygroscopicity and / or bioavailability. The present invention solves these problems.
[0009] Cocrystals are different from salts because, unlike salts, the components coexisting in a defined stoichiometry in the cocrystal lattice interact in a non-ionic manner. It is generally believed that when the ΔpKa (ΔpKa = pKa (conjugate acid of the base) - pKa (acid)) of the active pharmaceutical ingredient (API) and its cocrystal-forming compound (coformer) is <1, there will be insufficient substantial proton transfer. If this criterion is met, the API-coformer entity should be classified as a cocrystal. (Regulatory Classification of Pharmaceutical Co-Crystals Guidance for Industry, February 2018, http: / / www.fda.gov / Drugs / GuidanceComplianceRegulatoryInformation / Guidances / default.htm ).
[0010] Cocrystal formation can change several properties, such as melting point (which is considered one of the primary physicochemical properties to be considered), storage stability, solubility, dissolution rate, hygroscopicity and bioavailability, etc. (Izutsu, K et al, Characterization and Quality Control of Pharmaceutical Cocrystals, Chem. Pharm. Bull. 64, 1421-1430 (2016)).
[0011] Given the availability of a large number of pharmaceutically acceptable coformers and the lack of correlation between the properties of pharmaceutically acceptable coformers and the final properties of the corresponding cocrystals, finding suitable cocrystals is a difficult process and the outcome of which is a priori unpredictable.
[0012] There is a need to provide co-crystals of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid that improve the physicochemical and pharmaceutical properties, in particular improve the hygroscopicity without adversely affecting other important parameters such as the crystallinity or bioavailability of the active compound. In particular, it is necessary to reduce the hygroscopicity of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid under the usual conditions of pharmaceutical storage (<75% RH) while ensuring a good level of stability and solubility, in order to obtain improvements in the production, handling, storage and pharmaceutical properties of the acid. Summary of the invention
[0013] The present invention provides a co-crystal of (1R, 3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid.
[0014] After attempting to obtain cocrystals of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid with a number of potential crystal-forming compounds, the inventors surprisingly discovered that gentisic acid, urea and nicotinamide exhibit particularly good hygroscopicity and bioavailability properties and higher melting points relative to the free acid forms of the compounds. The improvements in the above properties mean advantages in the production, handling and storage processes of the compounds as well as the pharmaceutical properties of the products. In particular, the cocrystal bodies of the present invention show a significant improvement in oral bioavailability, which will enable significantly lower doses of the compounds to be administered to achieve target therapeutic levels.
[0015] As far as the subject matter of the present invention is concerned, there is no disclosure in the known prior art concerning the preparation and use of any co-crystals of compounds belonging to the family of compounds disclosed in patent application WO 2009 / 044250 A1, let alone co-crystals of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid, let alone co-crystals with gentisic acid, urea and nicotinamide.
[0016] Thus, in a first aspect, the present invention relates to co-crystals of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid and a co-crystal forming compound selected from gentisic acid, urea and nicotinamide.
[0017] In a second aspect, the present invention relates to a method for preparing the co-crystal defined in the first aspect, comprising:
[0018] a) contacting (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid with a co-crystal forming compound selected from gentisic acid, urea and nicotinamide in the presence of a liquid, and
[0019] b) isolating the resulting co-crystal.
[0020] In a third aspect, the invention relates to a combination product comprising the co-crystal according to the first aspect and one or more therapeutic agents selected from angiotensin converting enzyme inhibitors (ACE inhibitors), angiotensin receptor antagonists, statins, beta-blockers, calcium antagonists and diuretics.
[0021] In a fourth aspect, the present invention relates to a pharmaceutical composition comprising the co-crystal according to the first aspect or the combination product according to the third aspect and a pharmaceutically acceptable excipient.
[0022] In a fifth aspect, the invention relates to a co-crystal according to the first aspect, a combination product according to the third aspect or a pharmaceutical composition according to the fourth aspect, for use as a medicament.
[0023] In a sixth aspect, the present invention relates to a cocrystal according to the first aspect, a combination product according to the third aspect or a pharmaceutical composition according to the fourth aspect for use in the treatment and / or prevention of diseases known to be ameliorated by A1 adenosine receptor antagonism. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1 The structure of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid is shown. 1 H NMR spectrum.
[0025] Figure 2 Shown is the XRPD pattern of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid.
[0026] Figure 3 The DSC graph of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid is shown, which shows an endothermic event with an onset at 179.59°C corresponding to the melting point of the compound.
[0027] Figure 4 The co-crystal of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid and gentisic acid of Example 2 is shown. 1 H NMR spectrum.
[0028] Figure 5The XRPD pattern of the co-crystal of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid and gentisic acid of Example 2 is shown.
[0029] Figure 6 The DSC graph of the co-crystal of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid and gentisic acid of Example 2 is shown, which shows an endothermic event starting at 181.69° C. corresponding to the melting point of the co-crystal.
[0030] Figure 7 The co-crystal of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid and urea of Example 3 is shown. 1 H NMR spectrum.
[0031] Figure 8 The XRPD pattern of the co-crystal of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid and urea of Example 3 is shown.
[0032] Fig. 9 The DSC graph of the co-crystal of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid and urea of Example 3 is shown, which shows an endothermic event starting at 197.7°C corresponding to the melting point of the co-crystal.
[0033] Fig.10 The co-crystal of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid and nicotinamide of Example 4 is shown. 1 H NMR spectrum.
[0034] Fig.11 The XRPD pattern of the co-crystal of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid and nicotinamide of Example 4 is shown.
[0035] Fig.12 The DSC graph of the co-crystal of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid and nicotinamide of Example 4 is shown, which shows an endothermic event starting at 189.55° C. corresponding to the melting point of the co-crystal.
[0036] Fig.13A DVS graph of the co-crystal of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid and gentisic acid of Example 2 is shown, which shows the weight change (in %) of the co-crystal as a function of relative humidity (RH).
[0037] Fig.14 A DVS graph of the co-crystal of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid and urea of Example 3 is shown, which shows the weight change (in %) of the co-crystal as a function of relative humidity (RH).
[0038] Fig.15 A DVS graph of the co-crystal of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid and nicotinamide of Example 4 is shown, which shows the weight change (in %) of the co-crystal as a function of relative humidity (RH).
[0039] Fig.16 A comparison between the DVS patterns of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid and the different cocrystals obtained in Examples 2, 3 and 4 is shown. DETAILED DESCRIPTION
[0040] This patent application discloses several cocrystals of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid. The following cocrystals are obtained from (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid and a cocrystal-forming compound selected from gentisic acid, urea and nicotinamide. They all show improved physicochemical and pharmacokinetic properties relative to the free acid.
[0041] Gentisic acid eutectic
[0042] The inventors surprisingly found that the co-crystal of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid and gentisic acid has the following advantageous properties:
[0043] 1) Stability under forced conditions (1 week) and in 4-week stability assays: No changes in crystallinity, color or any other aspect were observed in the co-crystals obtained.
[0044] 2) Hygroscopicity: It shows less hygroscopicity than the free acid, especially under the usual storage conditions of drugs (<75% RH).
[0045] 3) Bioavailability: The improvements in oral exposure and bioavailability of gentisic acid cocrystals compared to the free acid were surprising.
[0046] Thus, the gentisic acid cocrystals provide advantages for the preparation of solid dosage forms containing pharmacologically active compounds, which facilitate their handling and allow for better dosing regimens. Furthermore, the gentisic acid cocrystal bodies of the present invention are stable solids even under forced stabilization conditions. Such cocrystals are less hygroscopic than the free acid (particularly up to 75% RH), as can be seen in the examples comparing the moisture content changes achieved by the gentisic acid cocrystals (0.10% at 75% RH) and the free acid (0.43% at 75% RH).
[0047] Urea eutectic
[0048] The co-crystal of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid and urea was also prepared and found to have all the following advantages:
[0049] 1) Stability under forced conditions (1 week) and in 4-week stability assays: No changes in crystallinity, color or any other aspect were observed in the co-crystals obtained.
[0050] 2) Hygroscopicity: It shows less hygroscopicity than the free acid, especially under the usual storage conditions of drugs (<75% RH).
[0051] 3) Bioavailability: The improvements in oral exposure and bioavailability of urea cocrystals compared to the free acid were surprising.
[0052] Thus, the urea co-crystals provide advantages for the preparation of solid dosage forms containing pharmacologically active compounds, facilitating their handling and allowing for better dosing regimens. Furthermore, the urea co-crystal bodies of the present invention are stable solids even under forced stabilization conditions. Such co-crystals are less hygroscopic than the free acid (particularly up to 75% RH), as can be seen in the examples comparing the changes in moisture content achieved by the urea co-crystals (0.08% at 75% RH) and the free acid (0.43% at 75% RH).
[0053] Nicotinamide cocrystal
[0054] The inventors surprisingly found that the co-crystal of (1R, 3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid and nicotinamide has all the following advantages:
[0055] 1) Stability under forced conditions (1 week) and in 4-week stability assays: During both stability assays, no changes in crystallinity, color or any other aspect were observed in the co-crystals obtained.
[0056] 2) Hygroscopicity: It shows less hygroscopicity than the free acid, especially between 5-70% RH.
[0057] 3) Bioavailability: The improvements in oral exposure and bioavailability of nicotinamide cocrystals compared to the free acid are surprising.
[0058] Thus, the nicotinamide cocrystals provide advantages for preparing solid dosage forms containing pharmacologically active compounds, facilitating their handling and allowing for better dosing regimens. Furthermore, the nicotinamide cocrystal bodies of the present invention are stable solids even under forced stabilization conditions. Such cocrystals are less hygroscopic than the free acid (particularly in the range between 5-70% RH), as can be seen in the examples comparing the variation in moisture content achieved by the nicotinamide cocrystals.
[0059] As shown in Examples 5 to 8, the co-crystals obtained show improvements in melting point, hygroscopicity and bioavailability properties relative to the free acid.
[0060] Thus, a first aspect of the present invention relates to a co-crystal of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid and a co-crystal forming compound selected from gentisic acid, urea and nicotinamide.
[0061] In the context of the present invention, the term "cocrystal" is used to refer to a crystalline material composed of two or more different molecules in a defined stoichiometric ratio within the same crystal lattice, which interact through non-ionic and non-covalent bonds. Typically, a cocrystal consists of an API moiety such as (1R, 3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid and a cocrystal-forming compound (coformer, cocrystal former, guest molecule).
[0062] In the context of the present invention, the term "co-crystal forming compound" or "coformer" is used to denote a component that is generally solid at room temperature and that interacts non-ionically with the API in the crystal lattice.
[0063] In the context of the present invention, a liquid is any substance that is liquid at room temperature, e.g. at 25°C, preferably a class 1, 2 or 3 solvent according to ICH guideline Q3C (R6), preferably selected from water, methanol, ethanol, isopropanol, propanol, butanol, acetonitrile, ethyl acetate, isobutyl acetate, propan-2-one (acetone), methyl isobutyl ketone (MIBK), tetrahydrofuran (THF), 1,4-dihydrofuran (THF), 1,4-dihydrofuran (DIH) and 1,4-dihydrofuran (DIH). The solvents used were oxane, dichloromethane (DCM), p-xylene, diethyl ether, methyl tert-butyl ether (TMBE), and heptane.
[0064] In a preferred embodiment, the co-crystal is a co-crystal of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid and gentisic acid.
[0065] In a more preferred embodiment, the molar ratio of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid to gentisic acid in the co-crystal is comprised between 0.9 and 1.1, preferably 1:1.
[0066] In a more preferred embodiment, the co-crystal of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid and gentisic acid has a differential scanning calorimetry (DSC) thermogram including an endothermic peak at about 181.69°C.
[0067] In a more preferred embodiment, the co-crystal of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid and gentisic acid is characterized by showing an X-ray powder diffraction pattern including 2θ° peaks at 6.99, 13.29, 13.42, 14.02, 17.82 (all ± 0.20) 2θ°, wherein the X-ray diffraction pattern is measured using CuKα radiation. In a more preferred embodiment, the X-ray diffraction pattern includes 2θ° peaks at 6.99, 13.29, 13.42, 14.02, 17.82, 18.71, 21.09, 26.34, 26.58, 27.28, 28.24, 31.56 (all ± 0.20) 2θ°.
[0068] In another preferred embodiment, the co-crystal is a co-crystal of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid and urea.
[0069] In a more preferred embodiment, the molar ratio of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid to urea in the co-crystal is comprised between 0.9 and 1.1, preferably 1:1.
[0070] In a more preferred embodiment, the co-crystal of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid and urea has a differential scanning calorimetry (DSC) thermogram comprising an endothermic peak at about 197.7°C.
[0071] In a more preferred embodiment, the co-crystal of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid and urea is characterized in that it exhibits an X-ray powder diffraction pattern including 2θ° peaks at 8.32, 8.82, 13.86, 15.60, 16.47, 24.86 (all ± 0.20) 2θ°, wherein the X-ray diffraction pattern is measured using CuKα radiation. In a more preferred embodiment, the X-ray diffraction pattern comprises 2θ° peaks at 7.77, 8.32, 8.82, 13.86, 15.60, 16.47, 18.23, 18.94, 19.38, 19.86, 20.05, 20.71, 21.38, 21.84, 22.76, 23.02, 24.86, 26.10, 27.28, 28.40 (all ± 0.20) 2θ°.
[0072] In a preferred embodiment, the co-crystal is a co-crystal of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid and nicotinamide.
[0073] In a more preferred embodiment, the molar ratio of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid to nicotinamide co-crystal is comprised between 0.9 and 1.1, preferably 1:1.
[0074] In a more preferred embodiment, the co-crystal of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid and nicotinamide has a differential scanning calorimetry (DSC) thermogram including an endothermic peak at about 189.55°C.
[0075] In a more preferred embodiment, the co-crystal of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid and nicotinamide is characterized by exhibiting an X-ray powder diffraction pattern including 2θ° peaks at 6.40, 8.54, 11.75, 17.29, 20.88, 23.66 (all ± 0.20) 2θ°, wherein the X-ray diffraction pattern is measured using CuKα radiation. In a more preferred embodiment, the X-ray diffraction pattern comprises 2θ° peaks at 6.40, 8.54, 11.28, 11.75, 13.02, 17.29, 18.33, 19.56, 20.11, 20.55, 20.88, 21.36, 21.62, 22.73, 22.96, 23.66, 24.26, 24.46, 25.12, 26.17, 26.46, 27.53, 28.81, 29.36, 30.28, 32.96 (all ± 0.20) 2θ°.
[0076] In the present invention, the pKa of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid is 4.3. The ΔpKa between the free acid and the selected co-crystal forming compounds is <1, as shown in Table 1 below.
[0077] Table 1
[0078] Compound pKa conjugate base ΔpKa Gentisic acid Non-alkaline - Urea Non-alkaline - Niacinamide 3.4 0.9
[0079] General properties of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid cocrystals Preparation method
[0080] In another aspect, the present invention relates to a method for preparing the (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid eutectic of the present invention, comprising:
[0081] a) contacting (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid with a crystal-forming compound in the presence of a liquid, and
[0082] b) Isolation of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid-coformer cocrystal.
[0083] Step a) comprises contacting (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid with a crystal-forming compound selected from gentisic acid, urea and nicotinamide in the presence of a liquid. In one embodiment, contacting the two starting compounds can be performed by mixing them. In one embodiment, the mixture obtained from step a) can be seeded with small crystals of the desired co-crystal compound to promote precipitation, but this is not necessary to obtain co-crystals.
[0084] (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid was prepared using the method disclosed in patent application WO2009 / 044250A1, which is incorporated herein by reference.
[0085] In a specific embodiment, when the cocrystal forming compound is gentisic acid, in step a), the molar ratio of (1R, 3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid to gentisic acid is 0:9 to 1:1.5, preferably 1:1 to 1:1.5, preferably 1:1 to 1:1.2. Contacting the two starting compounds can be carried out by mixing them. The mixture of the two compounds can be carried out, for example, by magnetic stirring. The mixture can be a solution or a suspension. Preferably, step a) comprises preparing the mixture of acid and gentisic acid to the reflux temperature of a liquid forming a partial solution or suspension, preferably until a solution is obtained. In a specific embodiment, the mixture is preferably kept at reflux temperature and stirring for 30 minutes to 24 hours, more preferably for 5 hours to 18 hours, and still more preferably for 10 hours to 15 hours.
[0086] The liquid may be any suitable liquid that does not react with (1R, 3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid or gentisic acid. Preferably, the liquid is selected from alkanols, aliphatic hydrocarbons, aromatic hydrocarbons, ethers, ketones, esters, dichloromethane, chloroform, dimethyl sulfoxide, acetonitrile, water and mixtures thereof, preferably water, acetonitrile, methanol, isopropanol, ethyl acetate, acetone, methyl isobutyl ketone, methyl tert-butyl ether, tetrahydrofuran, dimethicone ... alkane, dichloromethane, xylene, heptane and mixtures thereof.
[0087] In another specific embodiment, when the co-crystal forming compound is urea, in step a), the molar ratio of (1R, 3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid to urea is 0.9:1 to 1:1.5, preferably 1:1 to 1:1.5, preferably 1:1 to 1:1.2. Contacting the two starting compounds can be carried out by mixing them. The mixture of the two compounds can be carried out, for example, by magnetic stirring. The mixture can be a solution or a suspension. Preferably, step a) comprises preparing the mixture of acid and urea to the reflux temperature of a liquid forming a partial solution or suspension, preferably until a solution is obtained. In a specific embodiment, the mixture is preferably kept at reflux temperature and stirring for 30 minutes to 24 hours, more preferably for 5 hours to 18 hours, and still more preferably for 10 hours to 15 hours.
[0088] The liquid may be any suitable liquid that does not react with (1R, 3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid or urea. Preferably, the liquid is selected from alkanols, aliphatic hydrocarbons, aromatic hydrocarbons, ethers, ketones, esters, dichloromethane, chloroform, dimethyl sulfoxide, acetonitrile, water and mixtures thereof, preferably acetonitrile, methanol, isopropanol, isobutyl acetate, acetone, methyl isobutyl ketone, dichloromethane, xylene, heptane and mixtures thereof.
[0089] In a specific embodiment, when the co-crystal forming compound is nicotinamide, in step a), the molar ratio of (1R, 3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid to nicotinamide is from 0:9 to 1:1.5, preferably from 1:1 to 1:1.5, preferably from 1:1 to 1:1.2. Contacting the two starting compounds can be carried out by mixing them. The mixture of the two compounds can be prepared, for example, by magnetic stirring. The mixture can be a solution or a suspension. Preferably, step a) comprises preparing the mixture of the acid and nicotinamide to the reflux temperature of a liquid forming a partial solution or suspension, preferably until a solution is obtained. In a specific embodiment, the mixture is preferably kept at reflux temperature and stirred for 30 minutes to 24 hours, more preferably for 5 hours to 18 hours, still more preferably for 10 hours to 15 hours.
[0090] The liquid may be any suitable liquid that does not react with (1R, 3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid or nicotinamide. Preferably, the liquid is selected from alkanols, aliphatic hydrocarbons, aromatic hydrocarbons, ethers, ketones, esters, dichloromethane, chloroform, dimethyl sulfoxide, acetonitrile, water and mixtures thereof, preferably acetonitrile, acetone, methyl isobutyl ketone and mixtures thereof.
[0091] As used herein, the term alkyl includes a straight or branched hydrocarbon chain having 1 to 12 carbon atoms, preferably 1 to 6 carbon atoms, and having no unsaturation. When the term alkyl is accompanied by an expression indicating the number of carbon atoms, such as C1-C3, it means that the alkyl has the specified number of carbon atoms, such as 1-3 carbon atoms.
[0092] As used herein, the term alkanol includes a straight or branched alkyl chain as previously defined connected to a hydroxyl (OH) group. Preferred alkanols are isopropanol, propanol, ethanol, methanol, butanol, tert-butanol, isobutanol and mixtures thereof, more preferably isopropanol, propanol, ethanol, methanol and mixtures thereof.
[0093] As used herein, the term aliphatic hydrocarbon refers to a linear, branched or cyclic compound consisting of carbon and hydrogen atoms, which is saturated or has one or more unsaturations (double or triple bonds), for example, one, two or three unsaturations; preferably has 5 to 12 carbon atoms, more preferably has 5 to 8 carbon atoms, still more preferably has 6 or 7 carbon atoms. Examples of aliphatic hydrocarbons are pentane, hexane, heptane, cyclopentane, cyclohexane and mixtures thereof, etc., preferably heptane and cyclohexane and mixtures thereof.
[0094] As used herein, the term aromatic hydrocarbon refers to an unsaturated cyclic compound consisting of carbon and hydrogen atoms that conforms to Huckel's rule, preferably having 6 carbon atoms in the ring, optionally substituted by one, two or three C1-C3 alkyl groups which may be the same or different. Examples of aromatic hydrocarbons are toluene and xylene and mixtures thereof.
[0095] As used herein, the term ether refers to a compound of the formula RO-R', wherein R and R' are selected from: (a) an alkyl chain as previously defined, (b) wherein R and R' together form an alkylenic chain -(CH2) m , m is an integer selected from 4 to 6, which is optionally substituted by C1-C3 alkyl, or (c) wherein R and R' together form -(CH2) n -O-(CH2) p - group, n and p are independently selected from integers from 1 to 3. Examples of ethers are diethyl ether, tert-butyl methyl ether, di Alkane, tetrahydrofuran, methyltetrahydrofuran and mixtures thereof, etc.
[0096] As used herein, the term ketone refers to a compound of formula RC(=O)-R', wherein R and R' are independently selected from alkyl groups as previously defined. Examples of ketones are acetone and methyl isobutyl ketone, mixtures thereof and the like.
[0097] As used herein, the term ester refers to a R-COOR' group, wherein R and R' are independently alkyl as previously defined. Examples of esters are ethyl acetate and isobutyl acetate and mixtures thereof.
[0098] As used herein, the term gentisic acid is used in this document to refer to the compound whose IUPAC name is 2,5-dihydroxybenzoic acid.
[0099] As used herein, the term urea is used in this document to denote a compound having the formula (NH2)2-C=O.
[0100] As used herein, the term nicotinamide is used herein to refer to the compound whose IUPAC name is 3-pyridinecarboxamide.
[0101] According to one embodiment of the present invention, the liquid in step a) is selected from water, methanol, ethanol, isopropanol, propanol, butanol, acetonitrile, ethyl acetate, isobutyl acetate, propan-2-one (acetone), methyl isobutyl ketone (MIBK), tetrahydrofuran (THF), 1,4-dihydrofuran (THF), oxane, dichloromethane (DCM), p-xylene diethyl ether, methyl tert-butyl ether (TMBE) and heptane and mixtures thereof.
[0102] The volume of liquid to be used in the method can be determined by a person skilled in the art. Preferably, a volume (in ml) of 1-50 times the molar amount of (1R, 3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid is used, more preferably between 1-10 times.
[0103] One skilled in the art can determine when the (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid cocrystal is formed by routine procedures, for example, using thin layer chromatography, nuclear magnetic resonance, or high performance liquid chromatography.
[0104] Once the co-crystals are formed, step b) is performed, namely isolating the obtained co-crystals by methods commonly used in the field of the present invention, for example, by filtration.
[0105] Preferably, step b) may further comprise the steps of washing the obtained co-crystal to remove impurities and drying the co-crystal. Washing is preferably performed with the same liquid as used in step a). Drying is preferably performed under vacuum and at room temperature.
[0106] Combinations and pharmaceutical compositions
[0107] The present invention further provides a combination product comprising a co-crystal of the present invention and one or more therapeutic agents selected from the group consisting of: a) angiotensin converting enzyme inhibitors (ACE inhibitors), b) angiotensin receptor antagonists, c) statins, d) beta blockers, e) calcium antagonists and f) diuretics.
[0108] Examples of ACE inhibitors are, for example, captopril, enalapril, benazepril and the like.
[0109] Examples of angiotensin receptor antagonists are, for example, losartan, azilsartan, irbesartan, eprosartan and the like.
[0110] Examples of statins are, for example, atorvastatin, fluvastatin, simvastatin, and lovastatin, among others.
[0111] Examples of beta-blockers are, for example, acebutolol, atenolol, betaxolol, carvedilol, and propranolol, among others.
[0112] Examples of calcium antagonists are, for example, amlodipine, verapamil, vidipine and isradipine.
[0113] Examples of diuretics are, for example, chlorothiazide, chlorthalidone, furosemide, and spironolactone, among others.
[0114] The combination product may be a pharmaceutical composition comprising the co-crystal and one or more therapeutic agents. Alternatively, in the combination product, the co-crystal and the one or more therapeutic agents are in different compositions.
[0115] Furthermore, the present invention also comprises a pharmaceutical composition comprising a co-crystal as defined above or a combination as defined above and a pharmaceutically acceptable excipient. In particular, the co-crystal is in a therapeutically effective amount. The therapeutic agent, when present, is also preferably in a therapeutically effective amount.
[0116] An "effective amount" or "therapeutically effective amount" of a drug or pharmacologically active agent refers to an amount of the drug or agent that is non-toxic but sufficient to provide the desired effect. An "effective" amount will vary from subject to subject, depending on the age and general condition of the individual, the specific active agent or agents, etc. Thus, it is not always possible to specify an exact "effective amount." However, in any individual case, an appropriate "effective" amount can be determined by a skilled artisan using routine experimentation.
[0117] The co-crystals of the invention and one or more therapeutic agents defined above may be administered simultaneously, sequentially or separately.
[0118] For example, simultaneous administration may be performed in the form of a composition comprising the co-crystal of the invention and one or more therapeutic agents as defined above, or, i.e. when they are not part of the same composition, by simultaneous administration, i.e. simultaneous administration of independently formulated co-crystals of the invention and one or more therapeutic agents as defined above.
[0119] Sequential administration preferably means administration of the cocrystals of the invention at one time point and administration of one or more of the above defined therapeutic agents at a different time point in a staggered manner.
[0120] Separate administration preferably means that the co-crystal of the invention and the one or more therapeutic agents defined above are administered independently of each other at different time points.
[0121] The term "pharmaceutically acceptable excipient" refers to a carrier, diluent or adjuvant administered with the active ingredient. Such pharmaceutical excipients can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, etc. Water or aqueous eutectic solutions and aqueous solutions of dextrose and glycerol are preferably used as carriers, especially injectable solutions.
[0122] Examples of pharmaceutically acceptable excipients for oral dosage pharmaceutical compositions of the present invention are conventional excipients known in the art, such as binders, for example, syrup, gum arabic, gelatin, sorbitol, gum tragacanth or polyvinylpyrrolidone; fillers, for example, lactose, mannitol, xylitol, sorbitol, sucrose, corn starch, calcium phosphate, sorbitol, glycine, dextrose, maltodextrin, dextran, dextrin, modified starch; glidants and tablet lubricants, for example, magnesium stearate, calcium stearate, stearic acid, zinc stearate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated castor oil, colloidal silicon dioxide, silicon dioxide, anhydrous colloidal silicon, glycerol , hydrogenated vegetable oil, mineral oil, polyethylene glycol, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate or talc; disintegrants, for example, starch, polyvinyl pyrrolidone, sodium starch glycolate, cross-linked polyvidone, microcrystalline cellulose, hydroxypropyl cellulose or sorbitan fatty acid esters; pharmaceutically acceptable wetting agents, such as sodium lauryl sulfate; water-soluble adjuvants, such as urea, betaine monohydrate, potassium sulfate, potassium acetate, mannitol; alkalizing agents, such as potassium carbonate, sodium carbonate, sodium bicarbonate, trisodium phosphate, tripotassium phosphate, trisodium citrate, tripotassium citrate; sweeteners, such as saccharin sodium, sodium cyclamate and aspartame; flavoring agents, such as menthol and peppermint oil.
[0123] The pharmaceutical composition of the present invention can be administered parenterally, orally or topically, preferably by the oral route.
[0124] In a preferred embodiment, the pharmaceutical composition is in a dosage form suitable for parenteral administration, such as a sterile solution, suspension or lyophilized product in a suitable dosage unit form. Suitable excipients, such as fillers, buffers or surfactants may be used.
[0125] The pharmaceutical composition can also be in solid or liquid oral form. Suitable dosage forms for oral administration can be tablets, capsules, syrups or powder solutions for solutions or oral suspensions, granules, sachets. Preferably, the dosage form is selected from tablets and capsules.
[0126] The above formulations will be prepared using standard methods, such as those described or contemplated in the Spanish and US Pharmacopoeias and similar references.
[0127] Medical Uses
[0128] The co-crystal objects of the present invention exhibit / maintain potent antagonist activity at the A1 adenosine receptor.
[0129] Therefore, the present invention also relates to the use of a co-crystal as described above, a combination product of a co-crystal of the invention as defined above and one or more therapeutic agents, or a pharmaceutical composition as defined above as a medicament.
[0130] This aspect may also be formulated as a co-crystal of the invention as described above, a combination product of a co-crystal of the invention as defined above and one or more therapeutic agents or a pharmaceutical composition as defined above, for the preparation of a medicament.
[0131] Another aspect of the invention relates to the use of a co-crystal of the invention as described above, a combination of a co-crystal of the invention as defined above and one or more therapeutic agents or a pharmaceutical composition as defined above for the treatment and / or prevention of diseases known to be ameliorated by A1 adenosine receptor antagonism.
[0132] This aspect may also be formulated as the use of a co-crystal of the invention as described above, a combination product of a co-crystal of the invention as defined above and one or more therapeutic agents, or a pharmaceutical composition as previously defined, for the preparation of a medicament for the treatment and / or prevention of diseases known to be ameliorated by A1 adenosine receptor antagonism.
[0133] This aspect may also be formulated as a method for the treatment and / or prevention of diseases known to be ameliorated by adenosine A1 receptor antagonism, comprising administering to a subject in need of such treatment a co-crystal of the invention as described above, a combination product of a co-crystal of the invention as defined above and one or more therapeutic agents or a pharmaceutical composition as defined above.
[0134] Diseases or conditions suitable for improvement by adenosine A1 receptor antagonism are selected from hypertension, heart failure, ischemia, supraventricular arrhythmias, acute renal failure or any other disease caused by fluid retention, myocardial reperfusion injury, asthma, allergic reactions, including but not limited to hypertension, heart failure, ischemia, supraventricular arrhythmias, acute renal failure, myocardial reperfusion injury, asthma, allergic reactions (including rhinitis and urticaria), scleroderma and autoimmune diseases such as multiple sclerosis. In a preferred embodiment, the disease or condition improved by A1 adenosine receptor antagonism is selected from heart failure, acute renal failure, asthma, arterial hypertension and intradialytic hypotension.
[0135] As used herein, the terms "treat," "treatment," and "treating" refer to reversing, alleviating, inhibiting the progression of the disease or condition to which the term applies or one or more symptoms of the disease or condition.
[0136] As used herein, the terms "prevent" and "preventing" refer to inhibiting the occurrence of the disease or condition to which such term applies, or one or more symptoms of such disease or condition.
[0137] In the use according to the invention, the co-crystal, combination product or pharmaceutical composition of the invention may be administered 1, 2, 3, 4 or 5 times a day. In use, the co-crystal, combination product or pharmaceutical composition of the invention may be administered until the symptoms of the disease or disorder to be treated are reversed, alleviated or inhibited in their progression.
[0138] The following non-limiting examples are intended to illustrate the invention and should not be construed as limiting the scope of the invention.
[0139] Example
[0140] General Description
[0141] 1 H NMR analysis. NMR analyses were recorded in DMSO-d6 on a Varian Mercury 400 MHz spectrometer equipped with a 5 mm broadband probe ATB 1H / 19F / X. Spectra were obtained by dissolving 5-10 mg of sample in 0.7 mL of deuterated solvent.
[0142] XRPD analysis. Diffraction measurements of starting materials and screening samples were performed under ambient conditions on a PANalytical X'Pert PRO θ-θ diffractometer with a 240 mm reflection geometry radius, equipped with Cu Kα radiation and a PIXcel detector, operating at 45 kV and 40 mA. Each sample was mounted on a zero-background silicon stand and rotated at 0.25 rev / s during data collection. The measurement angle range was 3.0-40.0° (2θ) with a step size of 0.013°. During the study, the scan speed for the starting material was 0.082° / s (40.80 s / step) and the scan speed for the generated samples was 0.328° / s (10.20 s / step).
[0143] DSC analyses were recorded with a Mettler Toledo DSC 2. The samples were weighed into a 40 μl aluminum crucible with a pinhole cover and heated from 25°C to 300°C at a rate of 10°C / min under nitrogen (50 ml / min).
[0144] Crystallization stability studies were conducted under accelerated stability conditions (40°C, 75 ± 5 RH%) for one week. Samples of each form stored on XRPD silicon holders were exposed in a climate chamber. It is worth noting that these conditions are very extreme (drastic) because the high surface exposed to storage conditions may favor possible crystallization transformations. Samples were analyzed regularly by XRPD to observe possible transformations.
[0145] Additional crystallization stability studies were performed under accelerated stability conditions (40°C, 75 ± 5 RH%). Cocrystal samples were stored in open vials and exposed in a climate chamber, maintaining exactly set conditions (40°C–75% RH ± 5 RH). These samples were analyzed once a week for 1 month.
[0146] Hygroscopicity studies. The hygroscopicity of the cocrystals was determined by DVS (Dynamic Vapor Sorption) using a Q5000 TA instrument. This is a gravimetric technique that measures the amount of water absorbed or desorbed by a sample at different relative humidities (RH). At each RH level, the sample mass must be allowed to reach gravimetric equilibrium (or exceed a time limit) before proceeding to the next humidity level. Adsorption and desorption isotherms were performed at 25 °C in the range 0–95% RH. The samples were not previously dried, but were exposed to 0% RH until a stable weight was reached before starting the DVS cycle. This equilibration step allowed the elimination of possible adsorbed humidity from the atmosphere. The relative humidity (RH) was controlled by a mixture of humid and dry nitrogen flows. The RH was kept constant until equilibrium (constant weight) was reached or a maximum time was reached, after which the RH was changed to the next level.
[0147] Example 1 .Synthesis of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid
[0148] The synthesis of the compound (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid is described in detail in patent application WO 2009 / 044250 A1, which is incorporated herein by reference.
[0149] 1 H-NMR (300MHz, DMSO-d6): δ = 1.88 (m, 4H), 1.99 (m, 1H), 2.22 (m, 1H), 2.79 ( m,1H),3.06(m,1H),7.57(m,3H),7.99(m,2H),12.37(s,1H),12.89(s,1H).
[0150] Figure 1 The structure of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid is shown. 1 H NMR spectrum.
[0151] Figure 2 Shown is the XRPD pattern of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid.
[0152] Figure 3 The DSC graph of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid is shown, which shows an endothermic event with an onset at 179.59°C corresponding to the melting point of the compound.
[0153] Example 2.Preparation of cocrystals of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid and gentisic acid
[0154] To a round-bottom flask equipped with a magnetic stirrer and containing a mixture of (1R, 3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid (300 mg, 0.88) and gentisic acid (169 mg, 1.10 mmol, 1.25 eq.), TBME (3 ml) was added. The resulting mixture was stirred at room temperature for 15 hours. Then, the suspension was filtered through a sintered funnel (porosity n°3) and washed with TBME (2×0.2 mL). After vacuum drying at room temperature, a cocrystal of (1R, 3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid and gentisic acid was obtained as a white solid.
[0155] Figure 4 The co-crystal of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid and gentisic acid in a 1:1 molar ratio of Example 2 is shown. 1 H-NMR spectrum.
[0156] The co-crystal of Example 2 was also characterized by XRPD. Figure 5 The corresponding graphs are shown and Table 2 shows the main peaks.
[0157] Table 2
[0158] Pos.[°2Th±0.2] Relative strength [%] 6.99 100 13.29 6.2 13.42 6.3 14.02 5.6 17.82 4.2 18.71 2.7 21.09 3 26.34 1.8 26.58 1.1 27.28 1.5 28.24 2.5 31.56 1.1
[0159] Figure 6 The DSC trace of the co-crystal of Example 2 is shown, which displays an endothermic event with an onset at 181.69°C corresponding to the melting point of the co-crystal.
[0160] Example 3 .Preparation of Cocrystals of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid and Urea
[0161] To a round-bottom flask equipped with a magnetic stirrer and containing a mixture of (1R, 3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid (260 mg, 0.77 mmol, 1.3 eq.) and urea (35.2 mg, 0.59 mmol), ACN (2 mL) was added. The resulting mixture was stirred at room temperature for 15 hours. Then, the suspension was filtered through a sintered funnel (porosity n°3) and washed with ACN (2×0.2 mL). After vacuum drying at room temperature, a co-crystal of (1R, 3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid and urea was obtained as a white solid.
[0162] Figure 7 The co-crystal of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid and urea in a molar ratio of 1:1 is shown. 1 H-NMR spectrum.
[0163] The co-crystal of Example 3 was also characterized by XRPD. Figure 8 The corresponding graphs are shown and Table 3 shows the main peaks.
[0164] Table 3
[0165] Pos.[°2Th±0.2] Relative strength [%] 7.77 7 8.32 27 8.82 100 13.86 31 15.60 19 16.47 18 18.23 17 18.94 6 19.38 14 19.86 16 20.05 15 20.71 10 21.38 7 21.84 5 22.76 7 23.02 11 24.86 19 26.10 6 27.28 16 28.40 6
[0166] Fig. 9 The DSC trace of the co-crystal of Example 3 is shown, which displays an endothermic event with an onset at 197.72°C corresponding to the melting point of the co-crystal.
[0167] Example 4 .Preparation of Cocrystals of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid and Nicotinamide
[0168] To a round bottle equipped with a magnetic stirrer containing (1R, 3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid (400 mg, 1.17 mmol, 2 eq.) and nicotinamide (71.5 mg, 0.59 mmol), MIBK (4 mL) was added. The resulting mixture was stirred at room temperature for 15 hours. The suspension was then filtered through a sintered funnel (porosity n°3) and washed with MIBK (3×0.2 mL). After vacuum drying at room temperature, a co-crystal of (1R, 3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid and nicotinamide was obtained as a white solid.
[0169] Fig.10The cocrystal of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid and nicotinamide in a molar ratio of 1:1 is shown. 1 H-NMR spectrum.
[0170] The co-crystal of Example 4 was also characterized by XRPD. Fig.11 The corresponding graphs are shown and Table 4 shows the main peaks.
[0171] Table 4
[0172] Pos.[°2Th±0.2] Relative strength [%] 6.40 100 8.54 55 11.28 11 11.75 64 13.02 20 17.29 70 18.33 24 19.56 32 20.11 15 20.55 11 20.88 41 21.36 12 21.62 13 22.73 19 22.96 29 23.66 44 24.26 12 24.46 23 25.12 19 26.17 13 26.46 11 27.53 7 28.81 12 29.36 8 30.28 15 32.96 5
[0173] Fig.12 The DSC trace of the co-crystal of Example 4 is shown, which displays an endothermic event with an onset at 189.55°C corresponding to the melting point of the co-crystal.
[0174] Example 5. Stability determination
[0175] The stability of the cocrystal form of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid under accelerated storage conditions (40°C, 75±5 RH%) for one to four weeks was studied. See the results in Table 5.
[0176] Table 5
[0177]
[0178] After the exposure time, the co-crystal remained stable according to XRPD analysis. No amorphization or the appearance of crystalline form was detected within the detection limit of the analytical conditions.
[0179] Example 6 . Hygroscopicity study
[0180] The table below (Table 6) shows the moisture content of the parent carboxylic acids and co-crystals from the hygroscopicity studies.
[0181] Table 6
[0182]
[0183] As can be seen from the table above, the cocrystals with gentisic acid and with urea are less hygroscopic than the free acid, especially at up to 75% RH. Figure 13-16 .
[0184] Example 7 .Oral bioavailability determination
[0185] The aim of this study was to investigate the plasma pharmacokinetics of different cocrystals obtained from (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid after single intravenous (IV) and oral (PO) administration in male Sprague-Dawley rats.
[0186] Animals were divided into two groups: Group 1 (IV: 1 mg / kg) and Group 2 (PO: 5 mg / kg). Animals in Group 1 and Group 2 were administered solutions of different cocrystals of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid in normal saline. Blood samples were collected from a group of three rats at each time point in labeled microcentrifuge tubes containing K2EDTA solution as an anticoagulant at pre-dose, 0.083, 0.25, 0.5, 1, 2, 4, 8, and 24 hours (IV) and pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, and 24 hours (PO). Plasma samples were separated by whole blood centrifugation and stored at less than -70 ± 10 °C until bioanalysis. All samples were analyzed by protein precipitation using acetonitrile and analyzed using a suitable for purpose LC-MS / MS method (LLOQ = 1.00 ng / ml). Using Phoenix The non-compartmental analysis tool of ELISA (version 6.3) was used to calculate pharmacokinetic parameters.
[0187] The main pharmacokinetic parameters obtained from Examples 1-4 are shown in Table 7 below.
[0188] Table 7
[0189]
[0190] po: oral administration (per os)
[0191] iv: intravenous administration
[0192] C max It refers to the maximum plasma drug concentration obtained after oral administration of the drug between the dosing time and the final observation time point.
[0193] AUC 最后 It refers to the area under the curve from the time of administration to the last observation time, which is greater than the limit of quantification.
[0194] Clearance is a measure of the body's ability to clear a drug from plasma and is calculated based on intravenous administration.
[0195] F% refers to bioavailability. The systemic availability of a compound after oral administration was calculated using the following equation:
[0196] F(%)=(AUC 最后 PO × dose IV / AUC 最后 IV × dose PO) × 100
[0197] As can be seen from the table above, the co-crystals with gentisic acid, urea and nicotinamide exhibited higher bioavailability compared to the free acid.
[0198] Example 8 .Comparative bioavailability determination in healthy volunteers
[0199] The healthy volunteers in this study are males 18 years of age or older in order to evaluate the comparative bioavailability of the compound of Example 2 with the compound of Example 1 under fasting conditions and to study the effects of a high-fat, high-calorie meal. The compounds will be administered orally as a single dose of Example 1 (5 mg) and Example 2 (7.3 mg). The study will adopt a randomized, open-label, four-fold crossover design.
[0200] To determine comparative bioavailability, AUC 0-t (AUC 0-t : The area under the plasma concentration-time curve from time 0 h to the last measurable concentration) and C max (C max : Maximum observed plasma concentration (peak exposure)) will be determined after each administration.
[0201] result
[0202] 16 volunteers were included in the study. In all volunteers, the base sample showed the absence of the compound of Example 1. Therefore, all data were included in all pharmacokinetic measurements and calculations without any adjustments. See Table 8.
[0203] Table 8
[0204]
[0205] *: Median and range
[0206] AUC 0-t = Area under the plasma concentration curve relative to time up to the last quantifiable sample (time t) calculated using the trapezoidal method.
[0207] AUC 0-∞ : The area under the curve with respect to time extrapolated to infinity is calculated as follows:
[0208] AUC 0-∞ =AUC 0-t +C t / ke,
[0209] Among them C tis the quantitative concentration at time t, and ke is the elimination constant. The latter will be calculated using linear regression analysis during the last monoexponential elimination phase (Phoenix WinNonLin). In all cases, at least three plasma concentration values will be used to define this phase.
[0210] C max : Maximum concentration.
[0211] t max = reach C max time.
[0212] The bioavailability of Example 1 was similar to that of Example 2, wherein the AUC 0-t and C max The AUC under fed conditions 0-t The 90% confidence intervals of the cases were all within the acceptable range of bioequivalence (80.00%–125.00%). max It was slightly higher when administered after a high-fat meal.
Claims
1. A eutectic consisting of: a) (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid, and b) gentisic acid, wherein the molar ratio of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid to gentisic acid in the cocrystal is 1:1, and wherein the co-crystal is characterized by showing an X-ray powder diffraction pattern comprising 2θ° peaks at 6.99, 13.29, 13.42, 14.02, 17.82±0.20 2θ°, wherein the X-ray diffraction is measured using CuKα radiation.
2. The co-crystal of claim 1, wherein the co-crystal has a differential scanning calorimetry (DSC) thermogram comprising an endothermic peak at 181.69°C.
3. A eutectic consisting of: a) (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid, and b) urea, wherein the molar ratio of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid to urea in the cocrystal is 1:1, and wherein the co-crystal is characterized by showing an X-ray powder diffraction pattern comprising 2θ° peaks at 8.32, 8.82, 13.86, 15.60, 16.47, 24.86±0.20 2θ°, wherein the X-ray diffraction is measured using CuKα radiation.
4. The co-crystal of claim 3, wherein the co-crystal has a differential scanning calorimetry (DSC) thermogram comprising an endothermic peak at 197.7°C.
5. A eutectic consisting of: a) (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid, and b) niacinamide, wherein the molar ratio of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid to nicotinamide in the cocrystal is 1:1, and wherein the co-crystal is characterized by showing an X-ray powder diffraction pattern comprising 2θ° peaks at 6.40, 8.54, 11.75, 17.29, 20.88, 23.66±0.20 2θ°, wherein the X-ray diffraction is measured using CuKα radiation.
6. The co-crystal of claim 5, wherein the co-crystal has a differential scanning calorimetry (DSC) thermogram comprising an endothermic peak at 189.55°C.
7. A method for preparing the co-crystal according to claim 1 or 2, comprising: a) contacting (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid with gentisic acid in the presence of methyl tert-butyl ether, wherein the molar ratio of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid to gentisic acid is 1:1 to 1:1.5, and, b) isolating said co-crystal.
8. A method for preparing a co-crystal according to claim 3 or 4, comprising: a) contacting (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid with urea in the presence of acetonitrile, wherein the molar ratio of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid to urea is from 0.9:1 to 1:1.5, and, b) isolating said co-crystal.
9. A method for preparing a co-crystal according to claim 5 or 6, comprising: a) contacting (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid with nicotinamide in the presence of methyl isobutyl ketone, wherein the molar ratio of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentanecarboxylic acid to nicotinamide is from 1:1 to 1:1.5, and, b) isolating said co-crystal.
10. A combination product comprising a co-crystal according to any one of claims 1 to 6 and one or more therapeutic agents selected from angiotensin converting enzyme inhibitors, angiotensin receptor antagonists, statins, beta-blockers, calcium antagonists and diuretics.
11. A pharmaceutical composition comprising the co-crystal according to any one of claims 1 to 6 or the combination product according to claim 10 and a pharmaceutically acceptable excipient.
12. Use of the co-crystal according to any one of claims 1 to 6, the combination product according to claim 10 or the pharmaceutical composition according to claim 11 for the preparation of a medicament for treating or preventing a disease selected from hypertension, heart failure, ischemia, supraventricular arrhythmia, acute renal failure, myocardial reperfusion injury, asthma, allergic reactions including rhinitis and urticaria, scleroderma and autoimmune diseases.
Citation Information
Patent Citations
New compounds as adenosine a1 receptor antagonists
WO2009044250A1
New compounds as adenosine a1 receptor antagonists
CN101835766A
Cilostazol cocrystals and compositions
CN102933205A
Amine salt of (1r,3s)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentane carboxylic acid
WO2018162505A1
